Browse Technologies

• 
• 
• 
• 

Vanderbilt researchers have identified a highly expressed microRNA crucial in angiotensin induced hypertension; and developed a therapeutic strategy that focuses on local or systemic administration of antisense microRNA to inhibit microRNA expression as treatment for vascular diseases. Promising data in animal models reveals that the inhibition of such microRNA not only prevents fibrosis but also reverses previously established aortic stiffening.

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).

Dravet syndrome is a lifelong form of epilepsy beginning in early childhood. Children with Dravet syndrome suffer aggressive seizures, impaired cognition, and an increased risk of premature death. Dravet syndrome does not respond to conventional anti-epileptic drugs, and current treatment regimens fail to fully elevate seizures. No disease modifying treatments exist. Researchers at Vanderbilt University have discovered a novel application of a known natural product in treating Dravet syndrome. This natural product could be beneficial to children suffering from Dravet syndrome in both reducing seizures and treating the underlying disease cause.